Replies to post #149734 on Biotech Values

[Summer2762]

Giving one more look at the Tivantinib PhII trial data, it becomes quite obvious to me that the c-MET+ biomarker overwhelmingly superior to all other biomarkers (histology, KRAS, and EGFR) in predicting Tivantinib benefits in treating NSCLC pts even in specific subgroups such as KRAS and EGFR wild/mutant pts.

Which P2 trial data? NSCLC? If yes, can you explain how you arrived at this conclusion? I have a total opposite opinion on that.